CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
A CAR-T cell therapy designed to target a cellular protein called the GPRC5D antigen has produced impressive results in its first clinical trial in patients with multiple myeloma. The 17 patients in the Phase 1 trial had undergone a median of six prior treatments for myeloma, many of whom had received CAR T-cell therapy targeting […]